Dysesthesia: retatrutide's new skin-sensation effect

Dysesthesia is an altered, often unpleasant sense of touch: tingling, burning, pins and needles, or skin that feels oversensitive to touch, heat or cold. It appeared as a side effect of retatrutide in the Phase 3 trials at rates well above placebo. It was mostly mild and rarely made people stop, but nobody has yet explained why it happens.

What dysesthesia feels like

Dysesthesia is a medical umbrella term. The trials grouped together a cluster of related reports: tingling, burning, pins and needles, numbness, and heightened sensitivity in which ordinary touch, warmth, cold or the pressure of clothing feels uncomfortable or painful.^[5] It is a sensory symptom, not a rash. Because the topline announcements only give a single combined figure, we do not yet know how the different types split, which parts of the body were most affected, or how long the symptoms lasted in a typical case.

How common it was

The figures below come from Lilly's announcements and, for TRANSCEND-T2D-1, the published Lancet paper.

Three patterns stand out. The effect is clearly linked to the drug: placebo rates are under 1% everywhere. It rises with dose in the two trials that report each arm separately. And it varies a lot between trials, from one in twenty in the diabetes trials to one in five on the top dose in TRIUMPH-4. The TRIUMPH-4 participants were heavier on average (84% started with a BMI of 35 or more) and the trial was smaller,^[2] so some of that spread may be chance, but the difference is large enough to want an explanation. The trials are described in TRIUMPH-1 and TRIUMPH-4.

How serious it was

Lilly's statements describe the events as generally mild, and said they did not seem to lead to discontinuation.^[5] The ADA presentation of the TRIUMPH-1 data in June 2026 kept the same characterisation.^[6] Overall drop-out rates because of side effects are on the discontinuation page; dysesthesia does not appear to be a major driver of them.

That is reassuring as far as it goes. "Mild" in a trial means it did not need treatment or stop daily activities. It does not mean pleasant, and one in eight people on the higher doses of TRIUMPH-1 experienced it over 80 weeks.

Is it new?

Mostly, yes. Analysts who followed the TRIUMPH-4 readout called it a new safety signal, because nothing on this scale had been seen with Lilly's earlier drugs.^[5] To be precise, though, altered skin sensation is not unknown in the class. The Wegovy SmPC reports events of this kind (dysaesthesia, paraesthesia, burning sensation, sensitive skin) in 2.1% of people on semaglutide versus 1.2% on placebo, mild to moderate.^[7] The Mounjaro SmPC also lists dysaesthesia among tirzepatide's adverse reactions.^[8] What is new with retatrutide is the size of the effect: five to twenty times the placebo rate, rather than roughly double.

Why it happens: not yet explained

We do not know. Lilly has not offered a mechanism, and the peer-reviewed TRIUMPH papers, which will carry the detail, are not yet published. Retatrutide differs from its relatives in activating the glucagon receptor, and it produces faster and larger weight loss, but whether either of those is the cause is a guess, and we will not dress a guess up as an explanation. Until the full data are out, "not yet explained" is the accurate statement. It is on the what we do not know yet list for that reason.

The "reta rash" and community reports

In online groups, people using unlicensed products describe "skin sensitivity", "reta rash", itching and burning. These reports cannot be attributed to retatrutide, for three reasons.

1. Nobody knows what was injected. Testing of vials sold as retatrutide has found wrong strengths, low purity and unknown fill material. See what is actually in the vials.
2. A rash is not dysesthesia. The trial finding is a change in sensation. A visible rash points towards an allergic reaction, an infection, or a contaminant, none of which the trials reported at these rates.
3. There is no placebo group and no counting. Trials found that around 1% of people on dummy injections reported dysesthesia. Self-reports have no baseline.

The community reports section summarises these themes without endorsing them. Any reaction to any product, licensed or not, can be reported to the MHRA through the Yellow Card scheme; reports on unlicensed products are exactly the ones regulators most need.

What is and is not known

Known: it is real, drug-related, dose-related, mostly mild, and rarely a reason to stop in a trial with clinical support.

Not known: the mechanism; how long it lasts; whether it fully resolves after stopping; whether it is more common in particular people; whether it reflects any underlying nerve change; and what it means when the product is not the trial drug.

Trial rates describe the trial product. An unlicensed product carries the drug's own risks plus unknown extra ones.